PD-1/PD-L1抑制剂在肝癌免疫治疗中的研究进展

Research progress of PD-1/PD-L1 inhibitor in immunotherapy for liver cancer

原发性肝癌是目前我国第4位常见恶性肿瘤,其恶性程度极高,传统治疗方法对晚期肝癌的治疗效果欠佳。随着肿瘤免疫治疗机制的进一步阐明,许多免疫检查点抑制剂类新药被研发,并广泛地用于临床治疗中,成为继手术、放疗、化疗和中医药特色诊疗后治疗恶性肿瘤的新模式。细胞毒性T淋巴细胞相关抗原4(CTLA-4)、程序性细胞死亡蛋白-1(PD-1)和程序性细胞死亡配体1(PD-L1)等免疫检查点是肿瘤免疫治疗的主要靶点。临床研究表明,PD-1/PD-L1抑制剂能使更多的肝癌患者获益,包括肝细胞肝癌(HCC)和胆管癌(ICC)2种主要的原发性肝癌。本文主要对以PD-1/PD-L1(程序性细胞死亡受体-1/程序性细胞死亡配体1)为靶点的肝癌免疫治疗中的研究进展进行综述。

Primary liver cancer was the 4th most common malignant tumor in China.Its malignancy was extremely high.Traditional treatment methods were not effective in treating advanced liver cancer.With the further elucidation of tumor immunotherapy mechanisms,many new drugs had been developed in the field of immune checkpoint inhibitors and widely used in clinical treatment,becoming a new mode for the treatment of malignant tumors following surgery,radiotherapy chemotherapy and traditional Chinese medicine treatment.Immune checkpoints such as cytotoxic T lymphocyte-associated antigen 4(CTLA-4),programmed cell death-1(PD-1)and programmed cell death ligand 1(PD-L1)were the main targets of tumor immunotherapy.Clinical studies had shown that PD-1/PD-L1 inhibitors could benefit more patients with liver cancer,including two major primary liver cancers:hepatocellular carcinoma(HCC)and intrahepatic cholangiocarcinoma(ICC).This article mainly reviewed the research progress in the immunotherapy of liver cancer targeting PD-1/PD-L1.